ENT Disorder Treatment Market By Drug Type (Antibiotics Drugs, Anti Inflammatory Drugs, Others), By Organ (Throat, Ear, Nose), By End User (Hospital and clinics, Homecare Settings, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global ENT disorder treatment market was valued at $2,370.59 million in 2021, and is projected to reach $4,496.58 million by 2031, registering a CAGR of 6.5% from 2022 to 2031.
Ear, nose and throat are vital parts of the body. Ear is the sensory organ which is responsible to hear sounds, and to maintain the overall balance of the body. Nose is another type of sensory organ which helps to recognize smell; it also works as a defense mechanism restricting the entry of foreign particles, whereas, the throat provides the passage for air, water, and food.
Malfunction in any of these organs due to various diseases can directly affect the quality of life. Some of the common types of ENT disorders are ear-infection, sinus infection, tonsilitis, acoustic neuroma, Meniere’s disorder and others. The ENT disorder treatment consists of wide range of drugs such as nasal decongestion sprays, oral and topical anti-histamines, nasal steroids and nasal saline washes. Moreover, to treat ear infection a wide range of antibiotics are available; furthermore, a number of medical devices are also available to cure the presbycusis.
The key factors that drive the growth of market are rapid changes in environmental conditions and the increase in the level of air and noise pollution and rise in geriatric population. As geriatric population is more susceptible to get infected easily due to poor immune system which further propels the growth of the market. For instance, according to the report published by the technical group on population projections for India, about138 million were aged above 60 in India in 2021 and this is further expected to increase in 2031. Thus, increase in the geriatric population surged the demand for ear drops, and antibiotics to treat nasal, ear & throat infection, which drives the growth of the market.
Moreover, rise in the prevalence of sinusitis and chronic rhinitis across the world further drives the growth of market. In addition, rise in healthcare expenditure and increase in government initiatives in developing countries are the key factors that further boost the market growth
However, the high cost of medical devices and for the surgeries for sinusitis and tonsillitis hampers the market growth. Conversely, emerging healthcare market in developing countries is expected to provide the lucrative opportunity for the growth of market during the forecast period.
The ENT disorder treatment market is segmented on the basis of drug type, organ, end user and region. By drug type it is segmented into antibiotics, anti-inflammatory and others. By organ, it is segmented into ear, nose and throat. By end user the market is segmented into hospitals and clinics, homecare settings and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for a majority of the ENT disorder treatment market share in 2021 and is anticipated to remain dominant during the forecast period owing to the increase in the healthcare expenditure of this region and presence of major players in the country and the strategies they adopt for their product development.
Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to increase in the environmental pollution, rise in geriatric population and rise in prevalence of nasal infection, infectious and allergic conditions.
The key players that operate in the ENT disorder treatment market are Sanofi, Novartis, GSK, Pfizer, Vitaris, Sun Pharma, AstraZeneca, Cipla, AurbindoPharma, Teva Pharmaceuticals, Bayer AG, Amneal Pharmaceuticals Ltd, M.M Pharma, Lyra Therapeutics, Lannet Company Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ent disorder treatment market analysis from 2021 to 2031 to identify the prevailing ent disorder treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the ent disorder treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global ent disorder treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
Antibiotics Drugs
Anti Inflammatory Drugs
Others
By Organ
Throat
Disease Type
Tonsillitis
Pharyngitis
Tonsillopharyngitis
Others
Ear
Disease Type
Otitis Media
Otitis Externa
Meniere’s Disease
Otomycosis
Others
Nose
Disease Type
Sinusitis
Rhinitis
Nasal Polyps
Others
By End User
Others
Hospital and clinics
Homecare Settings
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia- Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc
Teva Pharmaceuticals
Novartis
Glaxosmithkline plc
Bayer Ag
Sanofi
Amneal Pharmceuticals Ltd
Astrazenca Plc
Mylan N.V.
Akira Healthcare
Aurbindo pharma
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook